Tumor Biology

, Volume 36, Issue 1, pp 233–238 | Cite as

Genetic variations in monocyte chemoattractant protein-1 and susceptibility to ovarian cancer

  • Li Li
  • Jinshan Zhang
  • Xin Weng
  • Ge Wen
Research Article


Monocyte chemoattractant protein-1 (MCP-1) is a chemokine which plays critical roles in regulating host immune responses. Researches have shown that MCP-1 may greatly participate in the development of different cancers. In the current study, we investigated the effect of MCP-1 on ovarian cancer by examining the association between MCP-1 genetic polymorphisms and the susceptibility to ovarian cancer. MCP-1 −2158A/G and MCP-1 −362C/G polymorphisms were examined in ovarian cancer patients and healthy controls by using polymerase chain reaction–restriction fragment length polymorphism analysis. Results showed that percentages of MCP-1 −2158GG genotype and G allele were significantly higher in ovarian cancer patients than in controls (odd ratio (OR) = 1.87; 95 % confidence interval (CI), 1.19–2.76; P = 0.012 and OR = 1.47; 95 % CI, 1.11–1.79; P = 0.003; data were adjusted for age and smoking status). The MCP-1 −362GG genotype also revealed increased number in patients. Stratification analyses presented that ovarian cancer cases with serous-papillary type had significantly increased percentage of −362GG genotype than those with other types (13.1 versus 5.0 %, P = 0.032; data were adjusted for age and smoking status). Also, we evaluated the relation between these two polymorphisms and serum level of MCP-1. We identified that the subjects with MCP-1 −2158AG and GG genotypes had clearly increased serum level of MCP-1 than those with AA genotype. These data suggest that MCP-1 may be involved in the pathogenesis of ovarian cancer.


MCP-1 Polymorphism Serum Ovarian cancer 


Conflicts of interest



  1. 1.
    Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Ann N Y Acad Sci. 2013;1291:86–95.CrossRefPubMedGoogle Scholar
  2. 2.
    Wu J, Wei JJ. HMGA2 and high-grade serous ovarian carcinoma. J Mol Med (Berl). 2013;91:1155–65.CrossRefGoogle Scholar
  3. 3.
    Chen Y, Zhang L, Hao Q. Olaparib: a promising PARP inhibitor in ovarian cancer therapy. Arch Gynecol Obstet. 2013;288:367–74.CrossRefPubMedGoogle Scholar
  4. 4.
    Foulkes WD, Shuen AY. In brief: BRCA1 and BRCA2. J Pathol. 2013;230:347–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Graves DT. The potential role of chemokines and inflammatory cytokines in periodontal disease progression. Clin Infect Dis. 1999;28:482–90.CrossRefPubMedGoogle Scholar
  6. 6.
    Ikeda U, Matsui K, Murakami Y, Shimada K. Monocyte chemoattractant protein-1 and coronary artery disease. Clin Cardiol. 2002;25:143–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Luther SA, Cyster JG. Chemokines as regulators of T cell differentiation. Nat Immunol. 2001;2:102–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Robertson MJ. Role of chemokines in the biology of natural killer cells. J Leukoc Biol. 2002;71:173–83.PubMedGoogle Scholar
  9. 9.
    Li X, Loberg R, Liao J, Ying C, Snyder LA, et al. A destructive cascade mediated by MCP-1 facilitates prostate cancer growth in bone. Cancer Res. 2009;69:1685–92.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Lu Y, Chen Q, Corey E, Xie W, Fan J, et al. Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone. Clin Exp Metastasis. 2009;26:161–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Hasegawa Y, Takahashi N, Forrest AR, Shin JW, Kinoshita Y, et al. CC chemokine ligand 2 and leukemia inhibitory factor cooperatively promote pluripotency in mouse induced pluripotent cells. Stem Cells. 2011;29:1196–205.CrossRefPubMedGoogle Scholar
  12. 12.
    Shpacovitch VM, Feld M, Holzinger D, Kido M, Hollenberg MD, et al. Role of proteinase-activated receptor-2 in anti-bacterial and immunomodulatory effects of interferon-gamma on human neutrophils and monocytes. Immunology. 2011;133:329–39.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Soria G, Ben-Baruch A. The inflammatory chemokines MCP-1 and CCL5 in breast cancer. Cancer Lett. 2008;267:271–85.CrossRefPubMedGoogle Scholar
  14. 14.
    Steiner JL, Murphy EA. Importance of chemokine (CC-motif) ligand 2 in breast cancer. Int J Biol Markers. 2012;27:e179–85.CrossRefPubMedGoogle Scholar
  15. 15.
    Zhang J, Lu Y, Pienta KJ. Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. J Natl Cancer Inst. 2010;102:522–8.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Li X, Tai HH. Activation of thromboxane A2 receptor (TP) increases the expression of monocyte chemoattractant protein-1 (MCP-1)/chemokine (C-C motif) ligand 2 (MCP-1) and recruits macrophages to promote invasion of lung cancer cells. PLoS One. 2013;8:e54073.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Seok SJ, Lee ES, Kim GT, Hyun M, Lee JH, et al. Blockade of MCP-1/CCR2 signalling ameliorates diabetic nephropathy in db/db mice. Nephrol Dial Transplant. 2013;28:1700–10.CrossRefPubMedGoogle Scholar
  18. 18.
    Bai J, Li X, Tong D, Shi W, Song H, et al. T-cell immunoglobulin- and mucin-domain-containing molecule 3 gene polymorphisms and prognosis of non-small-cell lung cancer. Tumour Biol. 2013;34:805–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Bai J, Song H, Cai C, Zhang M, Xu S, et al. The association of monocyte chemotactic protein-1 and CC chemokine receptor 2 gene variants with chronic obstructive pulmonary disease. DNA Cell Biol. 2012;31:1058–63.CrossRefPubMedGoogle Scholar
  20. 20.
    Song H, Ma S, Cha Z, Chen L, Tong D, et al. T-cell immunoglobulin- and mucin-domain-containing molecule 3 genetic variants and HIV + non-Hodgkin lymphomas. Inflammation. 2013;36:793–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Li M, Knight DA, Synder L, Smyth MJ, Stewart TJ. A role for MCP-1 in both tumor progression and immunosurveillance. Oncoimmunology. 2013;2:e25474.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Zirn B, Samans B, Spangenberg C, Graf N, Eilers M, et al. All-trans retinoic acid treatment of Wilms tumor cells reverses expression of genes associated with high risk and relapse in vivo. Oncogene. 2005;24:5246–51.CrossRefPubMedGoogle Scholar
  23. 23.
    Monti P, Leone BE, Marchesi F, Balzano G, Zerbi A, et al. The CC chemokine MCP-1/MCP-1 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. Cancer Res. 2003;63:7451–61.PubMedGoogle Scholar
  24. 24.
    Arnold JM, Huggard PR, Cummings M, Ramm GA, Chenevix-Trench G. Reduced expression of chemokine (C-C motif) ligand-2 (MCP-1) in ovarian adenocarcinoma. Br J Cancer. 2005;92:2024–31.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Wojnarowicz PM, Breznan A, Arcand SL, Filali-Mouhim A, Provencher DM, et al. Construction of a chromosome 17 transcriptome in serous ovarian cancer identifies differentially expressed genes. Int J Gynecol Cancer. 2008;18:963–75.CrossRefPubMedGoogle Scholar
  26. 26.
    Kucukgergin C, Isman FK, Cakmakoglu B, Sanli O, Seckin S. Association of polymorphisms in MCP-1, CCR2, and CCR5 genes with the risk and clinicopathological characteristics of prostate cancer. DNA Cell Biol. 2012;31:1418–24.CrossRefPubMedGoogle Scholar
  27. 27.
    Sharma NK, Sharma SK, Gupta A, Prabhakar S, Singh R, et al. Predictive model for earlier diagnosis of suspected age-related macular degeneration patients. DNA Cell Biol. 2013;32:549–55.CrossRefPubMedGoogle Scholar
  28. 28.
    Zhang HF, Zhao MG, Liang GB, Song ZQ, Li ZQ. Expression of pro-inflammatory cytokines and the risk of intracranial aneurysm. Inflammation. 2013;36:1195–200.CrossRefPubMedGoogle Scholar
  29. 29.
    Araujo FA, Rocha MA, Capettini LS, Campos PP, Ferreira MA, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (fluvastatin) decreases inflammatory angiogenesis in mice. APMIS. 2013;121:422–30.CrossRefPubMedGoogle Scholar
  30. 30.
    Mera S, Tatulescu D, Cismaru C, Bondor C, Slavcovici A, et al. Multiplex cytokine profiling in patients with sepsis. APMIS. 2011;119:155–63.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  1. 1.Department of Gynaecology, Affiliated Tumor HospitalXinjiang Medical UniversityUrumqiChina
  2. 2.Department of Radiation OncologyThe Third Affiliated Hospital of Guangzhou Medical UniversityGuangzhouChina
  3. 3.Department of GynaecologyThe Maternal and Child Health HospitalShandongChina

Personalised recommendations